Tempus Introduces TAAP, a Collaborative Research Platform to Develop and Deploy Algorithmic Diagnostics

Tempus, a leader in artificial intelligence and precision medicine, today announced its Tempus AI Advisors Program (TAAP), a platform that provides investigators access to the company’s multimodal database to enable development of novel clinical, molecular, and imaging-based algorithms to improve clinical care.

Through TAAP, Tempus is fostering additional research to identify novel clinical biomarkers and use them to develop algorithmic diagnostics that Tempus will validate and make available to physicians for clinical care. Tempus has already introduced a collection of these algorithmic tests in genetics, including Tempus|TO (Tumor Origin) and Tempus|HRD (Homologous Recombination Deficiency), which are available options with xT, Tempus’ 648-gene, broad-panel sequencing test.

The aim of TAAP is to scale the suite of algorithms that can analyze information across multimodal datasets – including pathology, genomics, and radiology – to connect the dots of a patient’s health and unlock new information that may inform their diagnosis, treatment options, or their fitness to participate in a clinical trial.

“We believe that algorithmic diagnostics have the potential to truly support personalized patient care by augmenting the insights produced by our existing tests,” said Chris Scotto DiVetta, Senior Vice President of AI Products at Tempus. “We recognize that there are many members of the broader scientific community who share our vision, and look forward to offering a platform that supports research that can have a meaningful impact on patient care.”

About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit

Related Content

View more